Neumora Therapeutics, Company Insiders
NMRA Stock | 1.14 0.06 5.00% |
Neumora Therapeutics, employs about 110 people. The company is managed by 18 executives with a total tenure of roughly 257 years, averaging almost 14.0 years of service per executive, having 6.11 employees per reported executive. Analysis of Neumora Therapeutics,'s management performance can provide insight into the company performance.
Neumora |
Neumora Therapeutics, Management Team Effectiveness
The company has return on total asset (ROA) of (0.405) % which means that it has lost $0.405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6448) %, meaning that it created substantial loss on money invested by shareholders. Neumora Therapeutics,'s management efficiency ratios could be used to measure how well Neumora Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Neumora Therapeutics, Workforce Comparison
Neumora Therapeutics, is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 34,922. Neumora Therapeutics, adds roughly 110 in number of employees claiming only tiny portion of equities under Health Care industry.
Neumora Therapeutics, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neumora Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neumora Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Neumora Therapeutics, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neumora Therapeutics, Notable Stakeholders
A Neumora Therapeutics, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Neumora Therapeutics, often face trade-offs trying to please all of them. Neumora Therapeutics,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Neumora Therapeutics,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MD FACP | CoFounder Advisor | Profile | |
Henry Gosebruch | CEO President | Profile | |
Paul Berns | CoFounder Chairman | Profile | |
Joshua Pinto | CFO Treasurer | Profile | |
Carol Suh | CoFounder COO | Profile | |
Jason JD | Chief Officer | Profile | |
Nicholas Brandon | Chief Officer | Profile | |
Amy Sullivan | Senior Resources | Profile | |
John Reynders | Chief Advisor | Profile | |
Maryjo ChamberlainTharp | Chief Officer | Profile | |
Kaya Panandiker | Chief Officer | Profile | |
Michael Milligan | Principal Officer | Profile | |
Robert MD | Head Development | Profile | |
Lori Houle | Chief Officer | Profile | |
Daljit PharmD | Chief officer | Profile | |
Jason Duncan | Chief Officer | Profile | |
Rajesh Manchanda | Chief Officer | Profile | |
Helen Rubinstein | Head Relations | Profile |
About Neumora Therapeutics, Management Performance
The success or failure of an entity such as Neumora Therapeutics, often depends on how effective the management is. Neumora Therapeutics, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Neumora management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Neumora management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the presentation of Neumora Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neumora Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neumora Therapeutics,'s management manipulating its earnings.
Neumora Therapeutics, Workforce Analysis
Traditionally, organizations such as Neumora Therapeutics, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Neumora Therapeutics, within its industry.Neumora Therapeutics, Manpower Efficiency
Return on Neumora Therapeutics, Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 2.2M | |
Net Loss Per Executive | 13.5M | |
Working Capital Per Employee | 2.6M | |
Working Capital Per Executive | 15.8M |
Complementary Tools for Neumora Stock analysis
When running Neumora Therapeutics,'s price analysis, check to measure Neumora Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neumora Therapeutics, is operating at the current time. Most of Neumora Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Neumora Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neumora Therapeutics,'s price. Additionally, you may evaluate how the addition of Neumora Therapeutics, to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |